August, 2019: BioAegis Therapeutics Reports Favorable Safety and Pharmacokinetic Results in its Phase 1b/2a Dose-Escalation Study of Recombinant Human Plasma Gelsolin with Highest Doses Ever Administered to Patients

MORRISTOWN, N.J., Aug. 07, 2019 (GLOBE NEWSWIRE) — BioAegis Therapeutics, Inc. announced the major findings from its Phase 1b/2a study of Recombinant Human Plasma Gelsolin for patients requiring hospitalization because of Community-Acquired Pneumonia.
This blinded placebo-controlled trial was a dose-escalation study with four cohorts of 8 patients randomized 3:1 to recombinant gelsolin versus placebo. The highest-dose cohort receive 3 consecutive daily doses of 24 milligrams per kilogram of body weight. As anticipated, no serious or drug-related adverse events were reported in what were the highest doses ever administered to patients. Furthermore, analysis of the pharmacokinetics demonstrated that the product half-life exceeded 12 to 16 hours which supports once-daily dosing.

See the full release here: 2019 08 06 Phase 1b 2a Results